The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial loss in